A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Tirzepatide Monotherapy Compared With Placebo in Chinese Participants With Type 2 Diabetes
Latest Information Update: 23 Oct 2024
At a glance
- Drugs Tirzepatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SURPASS-CN-MONO
- Sponsors Eli Lilly and Company
Most Recent Events
- 21 Oct 2024 Status changed from active, no longer recruiting to completed.
- 22 Jan 2024 Planned End Date changed from 14 Apr 2025 to 24 Sep 2024.
- 22 Jan 2024 Planned primary completion date changed from 14 Apr 2025 to 24 Sep 2024.